Obesity Drug Access Widens as CVS Health Adds Lilly Treatments to Standard Plans

CVS Health has announced expanded insurance coverage for two of Eli Lilly’s weight management drugs. Consequently, the move will significantly widen patient access. Millions of Americans rely on CVS for their pharmacy benefits, making this, therefore, a consequential shift.

Starting June 1, CVS will cover Foundayo, Lilly’s oral obesity medication. Additionally, coverage for Zepbound, the injectable weight-loss therapy, begins on October 1. Together, these changes represent one of the more significant formulary updates in the obesity drug space in recent years.

The announcement, furthermore, ends a coverage structure that had put Lilly at a disadvantage. Previously, CVS had given Novo Nordisk’s Wegovy preferred formulary status. As a result, Zepbound had been dropped from certain plans entirely. Under the new terms, however, both Zepbound and Wegovy now hold co-preferred status. This applies, accordingly, across a wide range of employer and commercial insurance plans.

Formulary placement drives patient access in this market. Indeed, high list prices make most patients heavily dependent on insurance coverage. Before this change, therefore, cost barriers had limited access to Lilly’s therapies. This was true even when a clinician considered them clinically appropriate.

Zepbound and Wegovy work through related but distinct mechanisms. Specifically, Zepbound targets two hormonal pathways, GIP and GLP-1. Both pathways, moreover, play a role in appetite regulation and energy balance. Meanwhile, Wegovy works on the GLP-1 receptor alone. Notably, the FDA has approved both as prescription treatments for chronic weight management. Eligibility is based, furthermore, on defined body mass index criteria.

Markets responded quickly. Indeed, Lilly’s shares climbed after the news. Similarly, CVS Health shares rose 0.98%, while Novo Nordisk gained 2.15% in the same session. Investors, therefore, viewed the co-preferred arrangement as a meaningful win for Lilly. The previous structure had, consequently, limited the company’s reach through one of the country’s largest pharmacy benefit managers.

Competition in the obesity treatment space, nevertheless, continues to intensify. Moreover, more manufacturers are entering the market. As a result, formulary decisions from major pharmacy benefit managers increasingly shape real-world prescribing patterns. Accordingly, prescription volume trends under the new CVS terms will be closely monitored. Furthermore, coverage decisions by other benefit managers could continue to reshape the competitive landscape between Lilly and Novo Nordisk.